According to recent reports, the success rate of targeted therapy directed by “actionable mutations” found in tumour DNA is rather low (10 to 20%). Interesting attempts have been made to improve this by establishing mouse ...

The abundance of rare variants in human DNA is the consequence of tremendous recent expansion of our population. Careful measurement of neutral variants in a European population points to more recent and more rapid expansion ...

One of the initial motivations for the Genome project was to improve the detection of possible mutations in children of atomic bomb survivors. In fact it has proved very difficult to find any genetic effect in these ...

Non-invasive prenatal testing is becoming commonplace, but, in addition, other tests using only a blood sample are being developed and will have a significant impact, notably in oncology.

New-generation sequencing is already in routine clinical use, notably for the search of actionable mutations in oncology, and for non-invasive prenatal diagnostics. More applications are developing and will soon enter ...

Three recent and very large projects aim to integrate several “omics” approaches in order to promote pro-active medicine and to create a “Wellness industry”.

The heterogeneity of tumours is now beginning to be documented precisely by single-cell new-generation sequencing. Recently published results on breast tumours show that each of the cells analysed displays a unique pattern ...

Very large-scale GWAS analyses confirm the genetic complexity of schizophrenia and provide some new leads to understand the etiology of the condition.